Skip to search formSkip to main contentSkip to account menu

ganirelix

Known as: D-Alaninamide, N-acetyl-3-(1-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-N6-(bis(ethylamino)methylene)-L-lysyl-L-prolyl-, ganirelix [Chemical/Ingredient], GnRH, N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)- 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
BACKGROUND A concern for new compounds in fertility treatment is the possible risk of perinatal complications or birth defects… 
2006
2006
Testosterone (T) secretion declines in the aging male, albeit for unknown reasons. From an ensemble perspective, repeated… 
2005
2005
BACKGROUND This randomized controlled trial was designed to evaluate whether a GnRH antagonist given every other day could… 
Highly Cited
2004
Highly Cited
2004
BACKGROUND The significance of suppressed LH levels in GnRH antagonist cycles for IVF outcome is currently unknown. The purpose… 
Review
2002
Review
2002
BACKGROUND To establish long-term safety, follow-up data on pregnancy, birth and neonatal outcome were collected during clinical… 
2001
2001
OBJECTIVE GnRH antagonists have recently been introduced for the prevention of premature LH surges during controlled ovarian… 
2000
2000
Recent suggestions that gonadotrophin-releasing hormone (GnRH) antagonists activate the GnRH receptor are discussed. Most of the…